Abstract
Increasing resistance of fungi, especially Candida spp., has successively reduced the already short list of effective antifungal drugs used in clinical therapy. Thus there is an urgent need for new, non-toxic antifungals with novel modes of action. A very interesting and attractive group of compounds seems to be complexes of Co(III) with diamine chelate ligands due to their therapeutic uses as antiviral, antibacterial, antifungal, antiparasitic, or antitumor agents. Two Co(III) complexes with diamine chelate ligands ([CoCl2(dap)2]Cl (1) and [CoCl2(en)2]Cl (2)) (where dap = 1,3-diaminopropane, en = ethylenediamine) were synthesized and characterized using elemental analysis, an ATR technique, and a scan method and sequentially tested to evaluate the mode of action. The assessment of cell damage by the newly synthetized photosensitive fluorescein-labelled complex 1 ([Co(dap)2FLU]Cl2) was performed using fluorescent microscopy, which indicated cell membrane permeability and altered cell morphology. The study of the C. albicans survival in blood showed a slight reduction in the number of viable, colonizing cells in the sample compared to the results obtained for the substances with confirmed antifungal activity – ketoconazole. DNA cleavage ability of the Co(III) complexes using agarose gel electrophoresis against genomic DNA isolated from a C. albicans cells showed nuclease activity for both complexes. This study provides new data on potential antifungal drugs, especially against Candida species.
Supplementary Materials
The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13231/s1, slides/poster.
Author Contributions
Conceptualization, methodology, and investigation, K.T. and A.C.; the biological component, K.T.; the chemical component, A.C.; formal analysis, K.T.; writing—original draft preparation, K.T.; writing—review, A.C., A.K. and K.W.; editing, K.T. and A.C. All authors have read and agreed to the published version of the manuscript.
Funding
This work was financially supported by the Ministry of Science and Higher Education Republic of Poland from the quality-promoting subsidy under the Leading National Research Centre (KNOW) programme 2012–2017 Faculty of Pharmacy with Subfaculty of Laboratory Medicine [dec. MNiSW-DS-6002-4693-23/WA/12].
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).